Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lirentelimab - Allakos

Drug Profile

Lirentelimab - Allakos

Alternative Names: AK 002; Antolimab

Latest Information Update: 31 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Anti-infectives; Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Antifibrotics; Eye disorder therapies; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis; Eosinophilic gastroenteritis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Conjunctivitis; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Fibrosis; Keratoconjunctivitis; Systemic mastocytosis

Most Recent Events

  • 31 Jan 2024 Discontinued - Phase-I for Conjunctivitis in USA (IV)
  • 31 Jan 2024 Discontinued - Phase-I for Eosinophilic gastroenteritis (In volunteers) in Australia (IV)
  • 31 Jan 2024 Discontinued - Phase-I for Eosinophilic gastroenteritis (In volunteers) in USA (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top